R
NA is growing in importance as a drug target 1 , but current approaches used to identify protein-targeting small molecules are ill suited for RNA. Most RNA targets lack the enzymatic activity required for conventional high-throughput screening, and their conformation-switching activity has proven difficult to assay experimentally [2] [3] [4] . Computational docking 5 can, in principle, provide the structural information needed to generally infer activity and can be used to screen uncharted regions of chemical space for novel RNA binders 6 . However, current protocols do not take into account the large conformational changes flexible RNA receptors undergo on binding small molecules, limiting discovery to compounds that target a narrow region of the structure landscape [7] [8] [9] . There is growing evidence that small molecules trigger RNA conformational changes by binding to conformers from pre existing dynamic ensembles [10] [11] [12] [13] [14] [15] [16] [17] . We have recently introduced a general approach 11 for visualizing RNA dynamic ensembles with the atomic resolution required for computational screening, and with extended timescales (less than milliseconds) needed to broadly sample the entire structure landscape. Here multiple sets of NMR residual dipolar coupling (RDC) data that report on the dynamics of bond vectors relative to elongated RNA helices 15 are used to guide selection 18 of conformers from a large pool generated using molecular dynamics (MD) 11 . By finding the minimum number of conformers that satisfy all time-averaged RDC data 19 , we constructed a compact ensemble that samples unique and dominant positions across the entire RNA structure landscape. This combination of experiment and theory is crucial for defining RNA ensembles, given that the conformational space that has to be sampled is vast and difficult to reduce, and that current force fields remain underdeveloped for RNA compared to proteins. Using this approach, we constructed a dynamic ensemble for the TAR (ref. 12 ) from HIV-1 and showed that the 20 conformers in the TAR NMR-MD ensemble include structures very similar to the structures observed when TAR is bound to seven distinct small molecules 11 ( Fig. 1a and Supplementary Results, Supplementary Fig. 1 ).
Here we show that docking small molecules onto RNA dynamic ensembles generated by NMR and MD solves the problem of taking into account large degrees of RNA conformational adaptation during virtual screening. Using this approach, we successfully identify six small molecules containing unidentified RNA-binding moieties that bind TAR with high affinity and inhibit its interaction with a Tat peptide in vitro (K i values ranging between 710 nM and 169 μM). One of the compounds binds HIV-1 TAR with marked selectivity through unique interactions involving both the bulge and apical loop and specifically inhibits Tat-mediated activation of the HIV-1 long terminal repeat by 81% in T cell lines and HIV replication in an HIV-1 indicator cell line (IC 50 ~23.1 μM). From these studies, a new strategy emerges for selectively targeting highly flexible RNAs.
RESULTS

Accurate docking against known bound RNA structures
Docking small molecules onto individual conformers within NMR-MD ensembles, rather than a single static conformation, provides a straightforward but as-of-yet unrealized approach for taking into account RNA conformational adaptation during virtual screening. Such an approach inherently assumes that computational docking can be used to predict RNA-small molecule interactions with sufficient accuracy when the structure of the small molecule-bound RNA is known. We therefore benchmarked binding predictions, using the Internal Coordinate Mechanics (ICM) 20 docking program, for the ideal case in which the small molecule-bound RNA structure is known.
We used a diverse set of 96 small molecule-bound RNA structures, 48 of which had corresponding experimental K d values. Structures with highly flexible small molecules (N flex > 20, where N flex is the number of flexible torsions in the small molecule) that pose conformational-sampling problems were excluded from ana lysis 21 . For each complex, the small molecule was removed, energy was minimized in the absence of RNA and the molecule was re-docked onto the target RNA structure using fully flexible small-molecule simulations. The RNA binding pocket, defined as all heavy atoms within 5 Å of the small molecule, was held rigid. In each case, the lowest docking score obtained from a specified number of iterations sampling different small-molecule conformations and poses was recorded (Supplementary Methods). The binding energies were predicted with very good accuracy (R = 0.71; Fig. 1b) , comparable to the accuracy obtained from state-of-the-art protein docking predictions 22 . More than half (53%) of the predicted binding poses match the X-ray or NMR structure to within a heavy atom r.m.s. deviation cutoff of 2.5 Å (Supplementary Fig. 2a ). This success rate compares well with the variability in the NMR bundle of structures, which typically results in an average r.m.s. deviation of 1.8 Å and in some cases >3 Å (ref. 23 ). Thus, the accuracy of docking predictions is not fundamentally limited by the scoring function or ability to sample different small molecule poses and conformations.
Overcoming 'adaptation' problem by docking RNA ensemble
A potentially more difficult problem in RNA computational docking is that the small molecule-bound RNA structure is generally not known, and it can vary substantially from small molecule to small molecule. This uncertainty can relegate docking predictions to computational oblivion, particularly for highly flexible RNA receptors, which tend to undergo very large structural changes on binding small molecules. However, the impact of such uncertainty has never been quantified in RNA docking simulations. As an initial test, we examined how well computational docking could be used to predict the experimental binding energies for 38 TAR-binding compounds when docking against available X-ray 24 and NMR 25 structures of apo-TAR. Notably, the quality of the docking predictions deteriorated abruptly (R = 0.13) so as to become completely uninformative and ineffective in lead-compound discovery (Supplementary Fig. 2b ). Docking against a computational (TAR MD ) ensemble consisting of 20 randomly chosen snapshots from an 80-ns MD simulation of apo-TAR 11 resulted in some improvement (R = 0.39), but nowhere near the accuracy attainable when the bound RNA structure was known (R = 0.71; Fig. 1b) . In this approach, each small molecule was independently docked onto each of the 20 conformers, and the lowest overall score, corresponding to the dominant interaction energy, was recorded. Thus, the accuracy of docking predictions is fundamentally limited by the uncertainty in the RNA-bound structure.
We examined whether we could recover the accuracy of docking predictions by docking small molecules against the 20 conformers in the TAR NMR-MD ensemble. This NMR-informed ensemble has previously been shown to sample many of the known ligand-bound TAR conformations 11 . Notably, the binding energies were now predicted with an accuracy (R = 0.66; Fig. 1c ) comparable to that attained when the bound RNA structure was known (R = 0.71; Fig. 1b) . These results reinforce the view that small molecules do not 'induce' new TAR conformations, but rather, 'capture' conformers from a pre-existing dynamic ensemble, and that TAR NMR-MD provides a good approximation for this ensemble.
Virtual screening TAR dynamic ensemble
The interaction between TAR and the viral transactivator protein Tat has long been targeted by researchers seeking to inhibit HIV replication, but this work has not yet resulted in clinically efficacious drugs 26 . We used our ensemble-targeted approach to identify TARtargeting compounds. Each of the 20 conformers in the TAR NMR-MD ensemble was subjected to virtual screening against ~51,000 small molecules (see Methods). The top 57 commercially available hits were tested using fluorescence-based assays (Supplementary Figs. 3 and 4) that probe binding to a TAR construct containing a fluorescent probe at bulge residue U25 (ref. 27 ) and inhibition of the interaction between TAR and an N-terminally labeled fluorescein peptide containing the arginine-rich motif of TAR's cognate protein target Tat 28 . We experimentally validated six small molecules in this manner, showing that they bind TAR (K d = 55 nM-122 μM) and inhibit its interaction with Tat (K i = 710 nM-169 μM) ( Table 1) .
Together with spermine ( Supplementary Fig. 5 ), the compounds were identified with a hit rate of 12%; the hit rate was as high as 50% when we focused only on water-soluble compounds that did not require DMSO in experimental assays (DMSO was not included in docking simulations). This can be compared to a hit rate of 0% in a screen of 57 randomly selected small molecules from the same libraries (Supplementary Data). The virtual screen also identified several small molecules, including two aminoglycosides, that were correctly predicted to bind TAR with much weaker affinity, despite their multiple positive charges. This was verified using fluorescence-based binding assays (Supplementary Fig. 6a ).
The six small molecules include previously unidentified compounds that add to the chemical diversity of known TAR-binding small molecules ( Table 1) . These compounds differ from recently developed cyclic peptides that bind TAR with high affinity and specificity 29, 30 , as well as from other TAR binders. For example, mitoxantrone (1; cationic groups, contains a novel RNA-binding scaffold consisting of a 5-chloropyrazin-2-amine core ( Table 1 ) and targets a unique pocket within the TAR apical loop (see below). This is a rare example of a small molecule binding exclusively to an RNA apical loop. The molecules also include the four semisynthetic aminoglycosides sisomicin (2; Table 1) , none of which has previously been shown to bind TAR.
Netilmicin binds TAR with high selectivity
The small molecules seem to have widely different specificities, as assayed using a competition experiment in which the K d is remeasured after the addition of 100-fold excess tRNA 33 ( Supplementary  Fig. 7) . Although we observed a substantial deterioration in the binding affinities of mitoxantrone, amikacin and sisomicin (K d values increased by factors of 27, 7 and 3, respectively), consistent with nonspecific binding to tRNA, we observed little to no change in the K d values for netilmicin and DMA, indicating that these compounds bind HIV-1 TAR with high specificity (Supplementary Fig. 7) . Notably, a single ethyl group substantially reduces the binding specificity of sisomicin as compared to netilmicin in this assay.
As a more stringent test of specificity, we used fluorescencebased assays to measure the binding affinities of the small molecules (excluding butirosin A, which became commercially unavailable at the onset of these experiments) for a panel of three RNAs that more closely resemble the TAR hairpin. These included an HIV-2 TAR variant (HIV-2) that differs from HIV-1 TAR by deletion of a single bulge residue, insertion of a G·U base pair and swapping of a G-C base-pair in the upper stem; the prokaryotic ribosomal A-site hairpin (A-site); and the HIV-1 rev response element hairpin (RRE). Both the A-site and RRE are binding sites for a broad range of aminoglycosides 34, 35 (Fig. 2a) . The binding assays (Supplementary Fig. 8a ) yielded specificity profiles for the various compounds that mirrored those observed with tRNA (Supplementary Fig. 7a) . Netilmicin showed the highest selectivity. It bound the closely related HIV-2 TAR with negligible affinity, and A-site and RRE RNA with one-thirty-fifth and oneeighty-sixth the affinity of HIV-1 TAR, respectively (Fig. 2b,c and Supplementary Fig. 8a ). As an even more stringent test, we measured the binding affinity of netilmicin to a TAR mutant that had a deletion of a single cytosine bulge residue. This mutant bound netilmicin with one-sixteenth the affinity of wild-type TAR (Supplementary Fig. 8a ). Once again, sisomicin showed markedly less specificity than netilmicin; it bound RRE with an affinity comparable to that for HIV-1 TAR (Fig. 2b,c) . As expected, DMA, which binds to the TAR apical loop (see below), showed strong selectivity against A-site and RRE but not against HIV-2 TAR (Fig. 2b,c) . All the other small molecules bound at least one other RNA with an affinity comparable to that for HIV-1 TAR ( Supplementary  Fig. 8a ). We confirmed these specificity trends with competition assays analogous to those described for tRNA, using the three RNA constructs as competitors (Supplementary Fig. 7a ).
Testing predicted binding modes using NMR
We tested the docking-predicted TAR-small molecule binding modes with site-specific resolution using NMR chemical shift mapping experiments. Many of the small molecules were predicted to bind conformers within a contiguous region (conformers 12-15) of the TAR NMR-MD structure landscape (Fig. 3a) characterized by near-coaxial alignment of the helices (interhelical bend angle <12°), as observed for TAR when bound to Tat mimics. Accordingly, all of the small molecules induced chemical shift perturbations characteristic of coaxial stacking of TAR helices as observed with Tat peptides and divalent ions 36 (for example, U23 and C24, Fig. 3b  and Supplementary Fig. 9 ). Notably, netilmicin, which showed the highest TAR binding specificity in vitro, was also predicted to bind conformers within the TAR ensemble with the highest specificity among aminoglycosides, with one conformer (18) accounting for 66% of the TAR population.
All six small molecules were predicted to bind TAR using distinct modes and to contact various combinations of residues in the bulge, upper stem and apical loop (Fig. 3c) that form crucial interactions with Tat, providing a structural basis for inhibiting the TAR-Tat interaction. Accordingly, the small molecules induce distinct chemical shift perturbations, particularly for residues predicted to be within the binding pocket (Fig. 3b,c and Supplementary  Fig. 9 ). Substantial perturbations (>0.1 p.p.m.) were observed for 87% of TAR sites predicted to be within 5 Å of the small molecule (Fig. 3c, red spheres) . Perturbations outside the 5-Å cutoff (Fig. 3c , green spheres) typically corresponded to nearby flexible residues, which probably change conformation on binding the small molecule. Even detailed aspects of the predicted binding modes are supported, in certain cases, by the NMR data (Fig. 3b,c and Supplementary Methods), including unique stacking of mitoxantrone on G26, distinct binding modes for netilmicin and sisomicin mediated by contacts involving netilmicin's unique ethyl group, and binding of DMA to a unique pocket within the TAR apical loop. Unlike other aminoglycosides and their conjugated derivatives that have been shown to bind the TAR bulge and upper and lower stems [37] [38] [39] , the aminoglycosides identified here, including netilmicin, interact with the apical loop in addition to the bulge and upper stem, while DMA provides a rare example of a small molecule that exclusively targets an RNA apical loop.
Netilmicin inhibits Tat activation of HIV-1 LTR
Of the five compounds tested (excluding butirosin A, which became commercially unavailable at the onset of these experiments), netilmicin, which binds TAR with the highest specificity in vitro (Fig. 2b) , inhibited Tat-mediated activation of the HIV-1 promoter by ~81% compared to the control (Fig. 4a) T cells using a luciferase reporter construct transfected into Jurkat T cells. The other four compounds did not show activity in this assay, probably owing to their much weaker binding specificities, though we cannot rule out other effects, such as differences between full-length Tat used in transfection assays and Tat peptides used in the in vitro displacement assay. As a control, we repeated measurements of netilmicin activity upon addition of phorbol 12-myristate 13-acetate (PMA), which activates the HIV-1 long terminal repeat (LTR) in a Tat-independent manner. If netilmicin does indeed block Tat-mediated activation of the HIV-1 promoter through its interaction with TAR, then no inhibition should be observed upon PMA-mediated activation. Indeed, netilmicin did not inhibit PMAmediated stimulation of the HIV-1 promoter, thus ruling out offtarget effects (Fig. 4a) .
To further assess the specificity of netilmicin, we measured its inhibitory activity toward an HIV-2 TAR promoter containing the same HIV-2 TAR sequence used in the binding assays (Fig. 2b) . According to in vitro binding data (Fig. 2b) , netilmicin binds HIV-2 TAR with negligible affinity. If the mode of action of netilmicin involves binding to TAR, we would predict it would be far less effective at inhibiting the stimulation of the HIV-2 promoter. Indeed, netilmicin did not inhibit stimulation of the HIV-2 promoter; rather, slightly greater activity was observed (Fig. 4b) . Moreover, no inhibition was observed when we used HIV-1 Tat to stimulate the HIV-2 transcriptional promoter, indicating that netilmicin does not bind and inhibit HIV-1 Tat, but rather, affects Tat-mediated transactivation through its interaction with HIV-1 TAR (Supplementary Fig. 10) . Thus, netilmicin specifically inhibits activation of the HIV-1 promoter but not the closely related HIV-2 promoter in cellular assays.
Netilmicin inhibits HIV-1 replication
Notably, netilmicin inhibited not only Tat activation, but also HIV-1 replication, as assayed using an HIV-1 indicator cell line, TZM-bl, and the HIV-1 NL4-3 isolate, which contains the same HIV-1 TAR sequence used in the in vitro studies. Addition of netilmicin to cells before and during infection resulted in substantially less HIV replication, yielding an IC 50 value (~23.1 μM; Fig. 4c ) strikingly similar to the value measured in vitro in the Tat displacement assay (K i = 14.1 μM; Table 1 ). The similarity of these inhibition constants further supports the idea that netilmicin inhibits HIV replication by targeting TAR. This IC 50 compares favorably with EC 50 values (ranging between 0.7 μM and 30 μM) measured using the same HIV-1 NL4-3 strain for the most potent aminoglycoside derivatives that have been designed as Tat mimetics, including, for example, the aminoglycoside-arginine conjugate of neomycin (NeoR6; EC 50 ~0.7 μM) 40 
.
We further corroborated the above results in an in vivo assay by infecting the HUT-78 T-cell line with HIV-1 NL4-3 in the presence of 100 μM netilmicin. Every 3 d, we assessed HIV-1 replication by measuring the amount of p24 antigen in the culture supernatants. Smaller amounts of p24 were observed for samples treated with netilmicin compared to vehicle alone, with the largest difference observed on day 9 (Fig. 4d) . Inhibition by netilmicin toxicity rather than TAR binding was ruled out, as trypan blue staining for cellular viability showed little difference between the vehicle-and netilmicin-treated cells (data not shown). Finally, our in vitro and cellular (gene reporter) assays showed that, despite its chemical similarity to netilmicin, sisomicin was far less effective at inhibiting Tat-mediated activation of the HIV-1 promoter, most probably because it binds TAR with substantially less specificity. If netilmicin inhibits HIV-1 replication by inhibiting the TAR-Tat interaction, we would expect sisomicin to be a far less potent inhibitor. Indeed, the IC 50 value (~157.1 μM) measured for sisomicin in the same HIV replication assay is about seven-fold higher than that measured for netilmicin (Fig. 4c) . This difference is substantial, considering that a two-fold increase in the IC 50 is typically observed with resistant viruses. These data provide additional support for the notion that netilmicin inhibits HIV replication by selectively inhibiting the TAR-Tat interaction, unlike NeoR and other aminoglycosidearginine conjugates, for which data suggest a different mode of inhibition involving the blocking of viral entry 40 .
DISCUSSION
Netilmicin is, to our knowledge, the first experimentally validated RNA-targeting compound with in vivo activity to be identified using a virtual screen. It has exquisite binding selectivity for HIV-1 TAR, and this seems to be an important determinant of its activity. This high specificity is achieved in part via a single ethyl substituent on a key cationic amine group ( Table 1) . Comparison of the binding modes of netilmicin and sisomicin reveals that this modification alone substantially reduces netilmicin's binding affinity for tRNA (Supplementary Fig. 7a ) and RRE (Fig. 2b,c) , without affecting its binding affinity for HIV-1 TAR. The alkyl group may stereochemically block access to the cationic group in the more rigid and less adaptable small molecule-binding pockets of tRNA and RRE, but not in the more flexible and malleable HIV-1 TAR. Consistent with this notion, reducing TAR's flexibility by deleting a single cytosine bulge residue that was not observed to make direct contacts with netilmicin, reduced netilmicin's binding affinity to one-sixteenth of its affinity for wild-type TAR (Supplementary Fig. 8a) . Previous studies have shown that the flexible TAR, compared with the less malleable A-site, is better able to accommodate conformationally restrained small molecules 41 . Stereochemical crowding of key cationic groups on small molecules may well prove to be a general strategy for enhancing selectivity toward highly flexible RNAs.
The method developed here for targeting highly flexible RNA receptors can also be implemented to target other highly flexible targets, including intrinsically unfolded proteins implied in neurodegenerative diseases for which traditional structure-and assaybased approaches have thus far failed, and for which NMR-informed computational dynamic ensembles are beginning to emerge 42 . Although five of the six newly identified TAR binders reported here have previously been shown to bind other RNAs, the compound library used in our virtual screen has been optimized for protein high-throughput screening and is not enriched with compounds that have favorable nucleic acid-binding properties. Our virtual screen can be scaled up to include millions of compounds that have advantageous nucleic acid-binding and drug-like characteristics. This will provide a much-needed route for efficiently screening new regions of chemical space in the search for novel RNA-targeting lead compounds.
METHODS
Virtual screening of TAR dynamic ensemble. Virtual screening simulations were performed with ICM (Molsoft) 20 using 20 TAR NMR-MD conformers and ~51,000 small molecules. TAR binding pockets were defined using the ICM PocketFinder module, and the protonation states of the small molecules were computed over pH 5.4-9.4 using the Major Microspecies module in the Calculator Plugin (ChemAxon). The small-molecule library (totaling 51,226 compounds) used in the virtual screening consisted of 49,166 compounds obtained from the Center for Chemical Genomics at University of Michigan and 2,060 compounds from our in-house library. Small molecules in the in-house library were identified from published reports of verified RNA-binding small molecules and drawn using ChemDraw (CambridgeSoft). Both libraries were saved in sdf file format. We started the virtual screening simulations by docking small molecules with N flex < 20 using a thoroughness of 1, followed by a second round of screening small molecules with the top ~10% of scores using a thoroughness of 10. The top 57 small molecules (58 including spermine) were subjected to experimental validation. The 57 small molecules were obtained from Maybridge, Chembridge, LKT Labs and Sigma, and with the exception of sisomicin (purity ≥80%), all were guaranteed to be ≥95% pure.
Fluorescence-based binding assay. The binding assay used a TAR construct labeled with 2-aminopurine at bulge residue U25. An alternative TAR construct labeled with fluorescein at the same residue was used to measure binding of small molecules whose absorbance spectra overlapped with the fluorescence of 2-aminopurine. Both RNAs were purchased from Integrated DNA Technologies. RNA was annealed by heating at 95 °C for 5 min followed by dilution (100 nM) into working buffer (10 mM phosphate, 20 mM NaCl, 0.1 mM EDTA pH 6.8) and cooling on ice for 2 h. Samples were pre-equilibrated for 5 min after addition of small molecule. Fluorescence intensity was measured using a Fluoromax-2 fluorimeter at an excitation wavelength of 320 nm and emission wavelength of 390 nm for 2-aminopurine, and an excitation wavelength of 485 nm and emission wavelength of 520 nm for fluorescein. Fluorescence-intensity measurements were recorded in triplicate and normalized to those of unbound TAR.
Fluorescence-based TAR-Tat displacement assay. The fluorescence polarizationbased displacement assay used an N-terminally fluorescein-labeled Tat peptide (N-AAARKKRRQRRR-C, Genscript) and an in vitro-synthesized elongated TAR. The elongated TAR was used to increase the dynamic range of fluorescencepolarization measurements. The TAR (60 nM) was incubated with varying concentrations of small molecules for 10 min, followed by another 10-min incubation with the addition of fluorescein-labeled Tat peptide (10 nM). The fluorescencepolarization buffer consisted of 50 mM Tris, 100 mM NaCl and 0.01% (v/v) nonidet-P40 at pH 7.4. The UV absorption spectrum was recorded for each small molecule tested, to ensure there was no spectral overlap with fluorescein. Fluorescence polarization was measured in triplicate using 384-well plates read with a PHERAstar Plus plate reader (BMG Labtech) with a 485-nm excitation wavelength and 520-nm detection wavelength for the optic module. IC 50 and K i values were calculated using the Prizm software (GraphPad Software). K i values and corresponding errors reported in Table 1 are within the 95% confidence interval.
NMR experiments.
All NMR experiments were performed at 25 °C with an Avance Bruker 600-MHz spectrometer equipped with a 5-mm triple-resonance cryogenic probe. NMR buffer consisted of 15 mM sodium phosphate, 0.1 mM EDTA, 25 mM NaCl and 10% D 2 O at pH ~6.4. NMR spectra were processed and analyzed with NMRPipe 43 and SPARKY 3 (http://www.cgl.ucsf.edu/home/sparky/). Cellular assays. In transfection assays, cells were pretreated with small molecule, or with vehicle or water (as controls), 24 h before transfection. Data shown in 
